Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 7/20 | 0.45 |
| ▸ | OGA | O60502 | 1/20 | 0.42 |
| ▸ | PYGB | P11216 | 1/20 | 0.40 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.36 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.36 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.35 |
| ▸ | FGF1 | P05230 | 1/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9914014 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL15081843 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL14025434 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL19980815 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL13471590 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL23603150 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL21077738 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL21083400 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL22423226 | 1.00 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 | |
| SCHEMBL12899675 | 0.92 | LGALS8 (0.45) | LGALS8OGAPYGBLGALS1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3274358-B1 | VACCINE AGAINST CARBAPENEM-RESISTANTKLEBSIELLA PNEUMONIAE | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS EV (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-8198419-B2 | Glycorandomization and production of novel erythromycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198419-B2 | Glycorandomization and production of novel erythromycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | THORSON JON | 2011-05-26 | — | — | US | disclosed |
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | THORSON JON | 2011-05-26 | — | — | US | disclosed |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-10-30 | — | — | US | disclosed |
| US-7348309-B2 | Glycorandomization and production of novel vancomycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348309-B2 | Glycorandomization and production of novel vancomycin analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2008020113-A1 | LUMINESCENT LANTHANIDE LABELLING REAGENTS AND THEIR USE | ABACUS DIAGNOSTICA OY (FI) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124850-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | LGALS8 1192/4885OGA 64/4885PYGB 1421/4885 |
| US-20120264924-A1 | Glycorandomization and Production of Novel Novobiocin Analogs | NMT2, NMT1, NAMPT | LGALS8 946/4885OGA 90/4885PYGB 882/4885 |
| US-20080268504-A1 | Glycorandomization and Production of Novel Vancomycin Analogs | NMT1, NMT2, B3GNT2 | LGALS8 1143/4885OGA 62/4885PYGB 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.